AskBio

Subsidiary of Bayer (BAYN)

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
GDNFGene therapy / editing
Parkinson's Disease

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
April 2028 (1)
Ametefgene parvecPhase 2PARKINSON DISEASE (Disorder)
Est. primary completion 2028-04-30 · NCT07215403 · CT.gov ↗
What to watch
August 2028 (1)
Ametefgene parvecPhase 2Parkinson Disease
Est. primary completion 2028-08-31 · NCT06285643 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.